How M.D. was paid
$15.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Joseph K. Belanoff, M.D.Chief Executive Officer and President | $1,182,333 | $1,190,000 | — | $12,907,718 | $23,500 | $15,303,551 |
| William Guyer, Pharm.D.Chief Development Officer | $706,387 | $429,600 | $17,871 | $5,163,087 | $23,500 | $6,340,445 |
| Sean MaduckPresident, Corcept Endocrinology | $648,860 | $261,200 | $111,995 | $5,163,087 | $23,500 | $6,208,642 |
| Atabak MokariChief Financial Officer and Treasurer | $566,347 | $285,000 | $97,733 | $5,163,087 | $23,500 | $6,135,667 |
| Charles RobbChief Business Officer and Secretary | $711,413 | $358,000 | $124,500 | $5,163,087 | $23,500 | $6,380,500 |
What changed and why
- $15.3MCEO total compensation increased to $15,303,551 in 2025 due to higher option award values and discretionary bonus amounts.
- $761.4MRevenue grew 13 percent to $761.4 million driven by a 37 percent increase in Korlym shipments.
- The FDA approved an NDA for relacorilant in platinum-resistant ovarian cancer more than 3 months ahead of schedule.
- 4%Base salaries for named executive officers increased by approximately 4 percent to 8.8 percent effective February 1, 2025.
- 94%Stockholders controlling 94 percent of voted shares approved the 2024 executive compensation program at the prior annual meeting.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.